7 studies found for:    cholangiocarcinoma AND transarterial approach | Open Studies
Show Display Options
Rank Status Study
1 Not yet recruiting A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma
Condition: Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: gemcitabine;   Drug: Cisplatin;   Drug: Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C
2 Recruiting TACE Plus Tegafur Versus TACE for Intrahepatic Cholangiocarcinoma After Curative Resection
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Procedure: TACE+Tegafur;   Procedure: TACE
3 Recruiting 90Y Transarterial Radioembolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Device: SIR-Spheres microspheres (Yttrium-90 Microspheres);   Drug: Gemcitabine;   Drug: Cisplatin
4 Recruiting Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin
Condition: Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Device: LC or ONCOZENE Bead with Gem-Cis or Gem-Carbo;   Drug: Gem-Cis or Gem-Carbo
5 Recruiting International Registry on Cholangiocarcinoma Treatment
Condition: Cholangiocarcinoma
Intervention: Drug: Doxorubicin
6 Recruiting Tremelimumab With Chemoembolization or Ablation for Liver Cancer
Conditions: Liver Cell Caricinoma;   Liver Cancer;   Hepatocellular Carcinoma;   Liver Neoplasms
Interventions: Drug: Tremelimumab;   Procedure: TACE;   Procedure: Radiofrequency Ablation (RFA);   Radiation: SBRT;   Procedure: Cryoablation
7 Recruiting A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
Conditions: Liver Cell Caricinoma;   Liver Cancer;   Hapatocellular Carcinoma;   Liver Neoplasms
Interventions: Drug: Durvalumab;   Drug: Tremelimumab;   Procedure: TACE;   Procedure: RFA;   Procedure: Cryoablation

Study has passed its completion date and status has not been verified in more than two years.